Tuberculosis vaccines: Progress and challenges

Trends in Pharmacological Sciences

Volumn 32, Issue 10, 2011, Pages 601-606

  Checkley, Anna M ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AERAS 402; AERAS 402 VACCINE; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; M 72; M 72 VACCINE; MODIFIED VACCINIA VIRUS ANKARA 85A VACCINE; MVA85A; UNCLASSIFIED DRUG; VIRUS VECTOR; VPM 1002; VPM 1002 VACCINE;

ANTIBIOTIC THERAPY; BCG VACCINATION; CLINICAL FEATURE; COUGHING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEVER; GOOD MANUFACTURING PRACTICE; HEMOPTYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOGENICITY; INCIDENCE; INFECTION SENSITIVITY; LUNG CAVITATION; LUNG GRANULOMA; MILIARY TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SPUTUM LEVEL; TUBERCULOSIS; TUBERCULOUS MENINGITIS; VACCINE PRODUCTION; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 80053351516     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.06.003     Document Type: Review

References (51)

1. World Health Organisation Global Tuberculosis Control 2010 2010 World Health Organisation
2. World Health Organisation Multidrug and Extensively Drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and Response 2010 World Health Organisation
3. C.L. Tseng Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study BMC Public Health 11 2011 55
4. S.D. Lawn, and A.I. Zumla Tuberculosis Lancet 378 2011 57 72
5. C.E. Barry, and 3rd The spectrum of latent tuberculosis: rethinking the biology and intervention strategies Nat. Rev. Microbiol. 7 2009 845 855
6. World Health Organisation Global Tuberculosis Control 2009 World Health Organisation
7. H. Mahomed The impact of a change in bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa Pediatr. Infect. Dis. J. 25 2006 1167 1172 (Pubitemid 44900682)
8. R. Wood Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa Int. J. Tuberc. Lung Dis. 14 2010 406 412
9. B.M. Buddle Update on vaccination of cattle and wildlife populations against tuberculosis Vet. Microbiol. 151 2011 14 22
10. G.A. Colditz Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature JAMA 271 1994 698 702 (Pubitemid 24061706)
11. B.B. Trunz Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness Lancet 367 2006 1173 1180
12. H. McShane Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans Nat. Med. 10 2004 1240 1244 (Pubitemid 39540442)
13. B. Abel The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults Am. J. Respir. Crit. Care Med. 181 2010 1407 1417
14. Y.A. Skeiky Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen Vaccine 28 2010 1084 1093
15. M.A. Horwitz, and G. Harth A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis Infect. Immun. 71 2003 1672 1679 (Pubitemid 36368696)
16. L. Grode Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin J. Clin. Invest. 115 2005 2472 2479 (Pubitemid 41266209)
17. N.L. Ferrer Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages PLoS ONE 5 2010 e12978
18. C. Vilaplana Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI Vaccine 28 2010 1106 1116
19. C.F. von Reyn Prevention of tuberculosis in Bacille Calmette-Guerin- primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine AIDS 24 2010 675 685
20. A.M. Cooper T cells in mycobacterial infection and disease Curr. Opin. Immunol. 21 2009 378 384
21. E.R. Rhoades Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis Tuber. Lung Dis. 78 1997 57 66 (Pubitemid 28019788)
22. T.V. Radaeva Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice Tuberculosis (Edinb.) 85 2005 65 72 (Pubitemid 40431317)
23. C. Aagaard A multistage tuberculosis vaccine that confers efficient protection before and after exposure Nat. Med. 17 2011 189 194
24. C.S. Aagaard Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis J. Immunol. 183 2009 2659 2668
25. D.J. Ordway Evaluation of standard chemotherapy in the guinea pig model of tuberculosis Antimicrob. Agents Chemother. 54 2010 1820 1833
26. A. Williams Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis Tuberculosis (Edinb.) 85 2005 29 38 (Pubitemid 40431313)
27. H.M. Vordermeier Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis Infect. Immun. 77 2009 3364 3373
28. C. Pirson Vaccines designed to protect against Mycobacterium tuberculosis infection may aid the identification of novel vaccine constructs and diagnostic antigens for bovine tuberculosis Vet. Microbiol. 148 2011 232 237
29. J.A. Langermans Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6 Vaccine 23 2005 2740 2750 (Pubitemid 40381267)
30. F.A. Verreck MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques PLoS ONE 4 2009 e5264
31. S.A. Sharpe Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing Clin. Vaccine Immunol. 17 2010 1170 1182
32. P.L. Lin Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model Infect. Immun. 77 2009 4631 4642
33. L.E. Via Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates Infect. Immun. 76 2008 2333 2340
34. C.R. Diedrich Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load PLoS ONE 5 2010 e9611
35. A. Williams Evaluation of new vaccines for tuberculosis in the guinea pig model Tuberculosis (Edinb.) 89 2009 389 397
36. C. Marwick Volunteers in typhoid infection study will aid future vaccine development JAMA 279 1998 1423 1424 (Pubitemid 28228181)
37. V.S. Moorthy Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA Vaccine 27 2009 5719 5725
38. F. Carrat Time lines of infection and disease in human influenza: a review of volunteer challenge studies Am. J. Epidemiol. 167 2008 775 785 (Pubitemid 351451744)
39. J. Statler Sonographic findings of healthy volunteers infected with dengue virus J. Clin. Ultrasound 36 2008 413 417
40. G. Walzl Immunological biomarkers of tuberculosis Nat. Rev. Immunol. 11 2011 343 354
41. B.M. Kagina Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns Am. J. Respir. Crit. Care Med. 182 2010 1073 1079
42. S.H. Cheon Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis Clin. Diagn. Lab Immunol. 9 2002 901 907
43. B. Kampmann Novel human in vitro system for evaluating antimycobacterial vaccines Infect. Immun. 72 2004 6401 6407 (Pubitemid 39429490)
44. B.J. Marais A refined symptom-based approach to diagnose pulmonary tuberculosis in children Pediatrics 118 2006 e1350 e1359
45. World Health Organisation The Global Plan To Stop TB 2011-2015 2011 World Health Organisation
46. R. Koch Fortsetzung der Mitteilungen ber ein Heilmittel gegen Tuberculose Dtsch. Med. Wschr. 17 1891 101 102
47. T. Hawkridge Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa J. Infect. Dis. 198 2008 544 552
48. A.C. Hesseling Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants Bull. World Health Organ. 87 2009 505 511
49. Global Advisory Committee on Vaccine Safety (2007) Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly. Epidemiol. Rec. 82, 193-196
50. M. Bongiovanni, and M. Casana Hepatitis B vaccination in HIV-infected subjects Curr. Mol. Pharmacol. 1 2008 191 194
51. M.O. Ota Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants Sci. Transl. Med. 3 2011 88ra56